Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I/II melanoma who did not undergo sentinel lymph node biopsy

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: TA reports personal fees for advisory board membership from Delcath and Philogen; personal fees as an invited speaker from Bristol Myers Squibb (BMS), Medscape, Neracare, Novartis and Pierre Fabre; personal fees for a writing engagement from CeCaVa and Medtrix; institutional fees as local principal investigator (PI) from Agenus Inc., AstraZeneca, BioNTech, BMS, HUYA Bioscience, Immunocore, IO Biotech, MSD, Pfizer, Philogen, Regeneron, Roche and University Hospital Essen; institutional fees as coordinating PI from Unicancer; institutional research grants from iFIT and Novartis; institutional funding from MNI - Naturwissenschaftliches und Medizinisches Institut, Neracare, Novartis, Pascoe, Sanofi and Skyline-Dx; non-remunerated membership of the American Society of Clinical Oncology (ASCO) and the Portuguese Society for Medical Oncology; a role as clinical expert in the area of medical oncology for Infarmed, and a role as an expert for SGA-Oncology at EMA. EC: No relationships to disclose. AL: No relationships to disclose. LN: No relationships to disclose. TS: reports institutional funding from Novartis and Pierre-Fabre outside the submitted work. HN: reports institutional funding from Novartis and Pierre-Fabre outside the submitted work. TA: reports stock and other ownership interests – SkylineDx B.V., Employment – SkylineDx B.V. RR: reports stock and other ownership interests – SkylineDx B.V., Employment – SkylineDx B.V. JD: reports stock and other ownership interests – SkylineDx B.V., Employment – SkylineDx B.V.; Leadership – SkylineDx B.V. and Honoraria – SciBase A.B. AE: reports stock and other ownership interests - IO Biotech, Sairopa B.V., SkylineDx B.V.; Honoraria Consulting or Scientific Advisory Role - Agenus, Boehringer Ingelheim GmbH, BioInvent, BioNTech, Brenus, CatalYm GmbH, Egle, Eurobio, ImmTech, IO Biotech, IQVIA, Merck KgA, Merck&Co, MSD, Oncolytics, Pierre Fabre, Sairopa BV, Secarna GmbH, SkylineDx B.V., Thermosome GmbH, Trained Immunity Therapeutics Discovery; Data safety monitoring board: BioNTech, IQVIA, Pfizer. UL: reports research support from MSD, consulting fees and honoraria from Sun Pharma, Sanofi (personal and institutional), MSD (personal and institutional), Novartis, Roche, Almirall Hermal, support for attending meeting from Sun Pharma and participation on a Data Safety Monitoring Board or Advisory Board from Sun Pharma, Sanofi, MSD, Novartis, Roche, Almirall Hermal, outside the submitted work. LF: reports Grants or contracts from Hookipa Pharma, SAKK / Immunophotonics, DFG Grant (Deutsche Forschungsgemeinschaft), Philogen and Mundipharma; consulting fees from Philogen, Sanofi, Novartis, BMS; participation on Data Safety Board University of Basel and stocks or stock options from Hookipa Pharma, outside the submitted work. SF: reports institutional funding from SkylineDx B.V. in relation with the submitted work; institutional grants from BioNTech and Neracare as well as personal honoraria for lectures from Recordati, Kyowa Kirin and Stemline Pharmaceutical, outside the submitted work.